Modern Medicines Series
SGLT2 Inhibitors: What we need to know
Over 3 programmes, Professor Cliff Bailey and colleagues will be providing concise evidence-based guidance to assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications.
Programme 3: SGLT2 inhibitors and the kidney
Professor Cliff Bailey - Emeritus Professor of Clinical Science, Aston University, Birmingham
Dr Pam Brown - GP, SA1 Medical Practice, Swansea
Taking place on Tuesday 9th March at 19:00 hours
These webinars are supported by Boehringer Ingelheim through an unrestricted educational grant:
The content, opinions and statements made in these webinars are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board and no liability is accepted for the consequences of any misleading or inaccurate information.